HAE

$58.58-0.32 (-0.54%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$58.58
Potential Upside
33.7%
Whystock Fair Value$78.35
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting sof...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.74B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
16.14
Beta
Defensive asset. Lower volatility than the S&P 500.
0.31
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
17.92%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.15

Recent News

Motley Fool
Mar 20, 2026

What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year

This medical technology firm delivers integrated blood management solutions to healthcare providers and plasma centers worldwide.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 15, 2026

Does Haemonetics' (HAE) Hospital Rebound and NexSys Expansion Reframe Its Competitive Positioning?

In recent months, Haemonetics has reported a recovery in its Hospital division, supported by broader adoption of its FDA-approved NexSys PCS system with Persona Technology and the completed transition away from older PCS2 devices. This operational progress, alongside the Attune Medica and OpSens acquisitions that expand its hospital and interventional cardiology offerings, signals a meaningful broadening of the company’s product base despite ongoing debt and competitive pressures. Next,...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 13, 2026

Why Is QuidelOrtho (QDEL) Down 24.5% Since Last Earnings Report?

QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
StockStory
Mar 13, 2026

2 Healthcare Stocks with Solid Fundamentals and 1 Facing Challenges

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have seen decent returns lately as healthcare stocks were up 3.8% over the past six months, almost identical to the S&P 500.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 12, 2026

Why Is Zimmer (ZBH) Down 2% Since Last Earnings Report?

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.